Key Biosimilars in Phase 3 Development
Several biosimilars targeting blockbuster drugs like Humira (adalimumab), Keytruda (pembrolizumab), and Stelara (ustekinumab) have advanced to late-stage trials. For Humira, Hadlima from Organon and Sandoz's adalimumab biosimilar are completing Phase 3 studies, with data showing comparable efficacy in rheumatoid arthritis patients.[1] Amgen's Wezlana (ustekinumab) for Stelara is in Phase 3, demonstrating non-inferiority in psoriasis treatment.[2] Samsung Bioepis's SB15 (pembrolizumab) for Keytruda has Phase 3 results pending FDA review, focusing on non-small cell lung cancer.[3]
Promising Phase 2 Biosimilars for Top Blockbusters
Phase 2 trials target drugs like Eylea (aflibercept) and Prolia (denosumab). Biocon's bdenosumab biosimilar for Prolia and Xgeva is in Phase 2, evaluating bone mineral density in osteoporosis.[4] Formycon's FYB202 (aflibercept) for Eylea is progressing through Phase 2, with interim data on retinal disease outcomes.[5] Intas Pharmaceuticals' adalimumab biosimilar remains active in Phase 2 for additional indications like Crohn's disease.[1]
Early-Stage Biosimilars in Phase 1
Phase 1 efforts focus on complex blockbusters such as Opdivo (nivolumab) and Darzalex (daratumumab). Celltrion's CT-P59 (nivolumab) is in Phase 1, assessing pharmacokinetics in healthy volunteers.[6] Prestige Biopharma's PBC501 (trastuzumab emtansine) for Kadcyla entered Phase 1 in 2023, targeting HER2-positive breast cancer safety.[7] JHL Biotech's ranibizumab biosimilar for Lucentis is conducting Phase 1 trials in wet AMD patients.[8]
When Do These Biosimilars Launch?
Launch timelines hinge on trial completion and approvals. Hadlima could hit markets by late 2024 post-patent settlements; Wezlana awaits EMA/FDA nods in 2024-2025.[2][9] Phase 1 candidates like CT-P59 face 4-6 years to market, delayed by patent challenges. Check DrugPatentWatch.com for patent expiry dates, such as Humira's key U.S. patents expiring 2023-2034 depending on formulation.[10]
Patent Hurdles Blocking Biosimilar Entry
Blockbuster patents often extend beyond data exclusivity, with Humira facing over 100 Orange Book listings litigated by AbbVie.[10] Keytruda's composition patents run to 2034-2036, prompting Phase 3 challengers like SB15.[11] Biosimilars can enter via "skinny labels" avoiding patented indications, as seen with some adalimumab approvals.
How Do Biosimilars Compare in Cost and Access?
These candidates promise 20-40% price cuts versus originators; Hadlima lists at $3,000-$4,000 per dose versus Humira's $6,000+.[12] Uptake lags in oncology due to physician trust, but rheumatoid arthritis biosimilars have captured 90%+ market share where available.[13]
Sources:
[1] ClinicalTrials.gov (Adalimumab)
[2] Amgen Press Release
[3] ClinicalTrials.gov (SB15)
[4] Biocon Pipeline
[5] Formycon FYB202 Update
[6] ClinicalTrials.gov (CT-P59)
[7] Prestige Biopharma
[8] JHL Biotech
[9] FDA Biosimilars Approvals
[10] DrugPatentWatch.com (Humira)
[11] DrugPatentWatch.com (Keytruda)
[12] GoodRx Pricing
[13] IQVIA Biosimilars Report